Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares OutstandingShares OutstandingShort-Term Debt repayments
Ratios

BioNexus Gene Lab (BGLC) Accumulated Depreciation & Amortization (2019 - 2025)

BioNexus Gene Lab's Accumulated Depreciation & Amortization history spans 7 years, with the latest figure at $944345.0 for Q4 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $944345.0 for Q4 2025, down 3.95% from a year ago — trailing twelve months through Dec 2025 was $944345.0 (down 3.95% YoY), and the annual figure for FY2025 was $944345.0, down 3.95%.
  • Accumulated Depreciation & Amortization for Q4 2025 was $944345.0 at BioNexus Gene Lab, down from $971148.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $994915.0 in Q1 2025 to a low of -$1.6 million in Q1 2021.
  • The 5-year median for Accumulated Depreciation & Amortization is $834883.0 (2022), against an average of $280660.6.
  • The sharpest move saw Accumulated Depreciation & Amortization plummeted 344.64% in 2022, then surged 163.02% in 2023.
  • Year by year, Accumulated Depreciation & Amortization stood at $574014.0 in 2021, then plummeted by 344.64% to -$1.4 million in 2022, then surged by 163.02% to $885004.0 in 2023, then grew by 11.09% to $983153.0 in 2024, then fell by 3.95% to $944345.0 in 2025.
  • According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $944345.0, $971148.0, and $943747.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.